Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) research hub

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

This clinical trial is testing a new nasal spray called cenegermin for adults with NAION, an eye condition causing sudden sight loss. Researchers want to see if this treatment helps repair damaged nerve cells and improves vision on an eye chart over a period of 24 weeks.